Baudax Bio Statistics
Total Valuation
Baudax Bio has a market cap or net worth of $89,527. The enterprise value is $7.82 million.
| Market Cap | 89,527 |
| Enterprise Value | 7.82M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Baudax Bio has 7.99 million shares outstanding. The number of shares has increased by 2,601.40% in one year.
| Shares Outstanding | 7.99M |
| Shares Change (YoY) | +2,601.40% |
| Shares Change (QoQ) | +63.63% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 0.00.
| PE Ratio | 0.00 |
| Forward PE | n/a |
| PS Ratio | 0.29 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 25.24 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.07
| Current Ratio | 0.07 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -48.50% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $34,444 |
| Profits Per Employee | -$795,000 |
| Employee Count | 9 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.46% in the last 52 weeks.
| Beta (1Y) | n/a |
| 52-Week Price Change | -99.46% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.22 |
| Relative Strength Index (RSI) | 42.38 |
| Average Volume (30 Days) | n/a |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Baudax Bio had revenue of $310,000 and -$7.16 million in losses.
| Revenue | 310,000 |
| Gross Profit | -4.48M |
| Operating Income | -24.37M |
| Pretax Income | -7.16M |
| Net Income | -7.16M |
| EBITDA | -6.92M |
| EBIT | -7.16M |
| Earnings Per Share (EPS) | $83.80 |
Balance Sheet
The company has $363,000 in cash and $8.10 million in debt, giving a net cash position of -$7.73 million or -$0.97 per share.
| Cash & Cash Equivalents | 363,000 |
| Total Debt | 8.10M |
| Net Cash | -7.73M |
| Net Cash Per Share | -$0.97 |
| Equity / Book Value | -10.24M |
| Book Value Per Share | -1.28 |
| Working Capital | -17.71M |
Cash Flow
In the last 12 months, operating cash flow was -$4.63 million and capital expenditures -$21,000, giving a free cash flow of -$4.65 million.
| Operating Cash Flow | -4.63M |
| Capital Expenditures | -21,000 |
| Free Cash Flow | -4.65M |
| FCF Per Share | -$0.58 |
Margins
Gross margin is -1,445.81%, with operating and profit margins of -7,860.32% and -2,308.06%.
| Gross Margin | -1,445.81% |
| Operating Margin | -7,860.32% |
| Pretax Margin | -2,308.06% |
| Profit Margin | -2,308.06% |
| EBITDA Margin | -2,230.65% |
| EBIT Margin | -2,308.06% |
| FCF Margin | -1,499.03% |
Dividends & Yields
Baudax Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2,601.40% |
| Shareholder Yield | -2,601.40% |
| Earnings Yield | -7,991.96% |
| FCF Yield | -5,190.59% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | 136.94% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Baudax Bio has an Altman Z-Score of -15.04 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -15.04 |
| Piotroski F-Score | 2 |